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Abstract The study focused on the application of high-
resolution mass spectrometry (HRMS) to postmortem
toxicological analysis. Fast and simple sample preparation
involved precipitation with acetonitrile, removal of phos-
pholipids using special columns and filtration. Qualitative
and quantitative analyses were performed using ultra-per-
formance liquid chromatography coupled with quadrupole
time-of–flight mass spectrometry. The method was vali-
dated by determining the limit of quantification, precision,
recovery and matrix effect. The use of a high-resolution
spectrometer allowed us to determine the precise masses of
the fragments of interest and to suggest the fragmentation
pathway of baclofen. The usefulness, effectiveness and
assets of the procedure were confirmed by an authentic
case of a 25-year-old woman fatally intoxicated with
baclofen who was found dead in her apartment. Toxico-
logical analysis of postmortem blood samples demon-
strated that the baclofen concentration was 30.7 lg/mL. In
only one published case describing fatal baclofen intoxi-
cation were no other xenobiotics (that could interact with
baclofen) found. To our knowledge, this is the first report
dealing with analysis of baclofen by HRMS.
Keywords Baclofen  Fatal intoxication  QTOF 
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Introduction
Baclofen [(±)-4-amino-3-(4-chlorophenyl) butanoic acid,
b-(aminomethyl)-4-chlorobenzenpropane acid, Fig. 1],
with commercial names of Atrofen, Baclofen, Lioresal
and Lyflex. Baclofen is a drug affecting the central ner-
vous system (CNS). The mechanism of action of baclofen,
which is a derivative of c-aminobutyric acid (GABA),
involves stimulation of GABAB-ergic receptors located
pre- and postsynaptically [1]. The substance decreases the
skeletal muscle tone by inhibiting the mono- and polysy-
naptic reflexes at the spinal cord level, but does not affect
the neuromuscular conduction [2]. Baclofen is used for the
treatment of spinal cord diseases, cerebral stroke and
cerebrospinal meningitis. It is also applied in patients with
severe chronic spasticity in multiple sclerosis [3, 4].
Moreover, the drug is known to minimize the symptoms of
alcohol craving [5–7].
Baclofen occurs as a mixture of two biologically active
enantiomers (R and S), that differ in the arrangement of
substituents around a chiral carbon atom. It has been found
that the R(-) isomer of baclofen exhibits about 100-fold
more potent pharmacological action than its S(?) form [8].
Wuis et al. [9] compared the pharmacokinetics of racemic
baclofen and its two enantiomers, and they have found that
the biological half-life (t) of R(-) baclofen is 4.5 h,
which is longer than the half-life of its racemic mixture
(3.8 h) as well as S–baclofen (2.9 h). These findings sug-
gest the existence of stereoselective renal elimination
pathways [9]. After its oral administration, baclofen is
rapidly and completely absorbed. It reaches the maximum
blood concentration after 2–3 h. The biological half-life is
2.5–4 h [10]. It is bound to blood proteins at a rate of about
30 %. Due to deamination and oxidation, 15 % of the
absorbed dose of baclofen is metabolized in the liver to b-
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(p-chlorophenyl)-c-hydroxybutyric acid whereas 85 % is
excreted intact into urine [11]. The oral therapeutic dose
for adults should be tailored individually and ranges
between 15–80 mg/day [3]; significant complications, and
life-threatening cases have been reported with doses as low
as 300 mg [12].
The literature reports of acute and fatal baclofen intox-
ication are rare, as compared to other CNS-affecting drugs
[13, 14]. In some cases, the symptoms of overdose occur
already during the use of the therapeutic dose and include
decreases in muscle tone, dizziness, sedation, seizures, loss
of consciousness, hypothermia, inhibition of the respiratory
function, apnoea and coma [15]. Long-term administration
followed by withdrawal can lead to psychotic, manic and
paranoid anxiety disorders [16].
To date, baclofen has been determined in various bio-
logical materials using the techniques based on gas [17, 18]
or liquid [19–21] chromatography, liquid chromatography–
tandem mass spectrometry [22–25] as well as capillary
electrophoresis [26]. However, the majority of these
methods require time-consuming sample preparation. As
far as medico-legal toxicology is concerned, it is essential
to design a simple and fast analytical procedure, providing
reliable results.
Substantial advances in the development of special
devices for identification and determination of chemical
compounds in biological material have recently been
observed. Thanks to equipment, increasingly more sub-
stances at markedly lower concentrations can be detected.
However, considering the interpretation of results and
established norms regarding, e.g. validation of methods,
much more attention should be paid to toxicological
analysis; therefore, numerous recent descriptions contain
detailed data regarding analytical problems associated with
examinations of the postmortem material [27–29]. In this
manuscript, high-resolutions mass spectrometry (HRMS)
was used for the determination of baclofen in postmortem
blood. The technique based on liquid chromatography–
hybrid quadrupole time-of-flight-mass spectrometry (LC–
QTOF-MS) enables comprehensive targeted forensic
screening. The use of this detector allows one to determine
the exact weight and elemental composition of an unknown
compound. To our knowledge, this is the first paper
describing the determination of baclofen in postmortem
blood by LC–QTOF-MS. The aim of the study was to
develop and validate a highly specific, simple and quick
method of determination of baclofen in biological material,
to analyze fragmentation of this substance and to review
the literature concerning baclofen intoxication cases.
Materials and methods
Chemicals and reagents
Water (Chromasolv LC–MS), acetonitrile (Chromasolv
LC–MS), methanol (Chromasolv LC–MS), gabapentin
and formic acid were purchased from Sigma-Aldrich
(Steinheim, Germany); (±)–baclofen was purchased from
Polpharma SA (Starogard Gdan´ski, Poland). Standard
solutions of baclofen were prepared in water. Gabapentin
[internal standard(IS)] was prepared in methanol. The
standard solutions were stored in a refrigerator at -20 C.
Blank human blood material
Four blank samples of postmortem human blood were
derived from the Chair and Department of Forensic Med-
icine. Blank samples did not contain any anticoagulant and
were screened prior to spiking to ensure that they were free
from baclofen and gabapentin.
Chromatographic conditions
Chromatographic analysis was performed using an ultra-
high performance liquid chromatograph (UHPLC Infinity
1290, Agilent Technologies, Waldbronn, Germany). The
separation was done employing a Poroshell 120 EC-C18
column (3.0 9 100 mm); 2.7 lm (Agilent Technologies,
Santa Clara, NM, USA).
A mixture of 0.1 % formic acid in water (A) and 0.1 %
formic acid in acetonitrile (B) was used as a mobile phase.
The gradient elution was carried out at constant flow rate of
0.4 mL/min in the following gradient mode: 0 min (95 %
A/5 % B); 0.5 min (70 % A/30 % B), 5 min (30 %
A/70 % B), 7 min (5 % A/95 % B) and 8 min (95 %
A/5 % B). Return to the initial conditions (95 %A) was
achieved 2.5 min after the 8-min long analysis. The
injection volume was 5 lL.
Mass spectrometry
Detection of the study compounds was achieved using a
quadrupole time-of-flight (QTOF) mass spectrometer
(QTOF 6540, Agilent Technologies, Santa Clara, NM,
Fig. 1 Structures of enantiomers of baclofen and the internal
standard (IS) gabapentin
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USA). The spectrometer was equipped with an electrospray
ionization (ESI) source. The source conditions were as
follows: gas temperature 350 C; gas flow 10 L/min.;
nebulizer (N2) 35 psi; sheath gas temperature 400 C;
sheath gas flow 12 L/min.; capillary voltage 3000 V;
fragmentor voltage 140 V; skimmer voltage 65 V; oct 1
RF Vpp 750 V; mass range m/z 50–1000. Quantitative and
qualitative analyses were carried out in the MS mode. To
ensure accuracy of mass measurements, reference mass
correction was used. Masses at m/z 121.0509 and 922.0098
were used as reference ions. The mass tolerance used for
the extracted ion chromatograms was ±20 ppm. The mass
error for the reference masses used prior to analysis was
lower than 2.7 ppm.
The analysis of product ion formation of baclofen at a
concentration of 5 lg/mL was carried out in the tandem
QTOF mode with spectral parameters: mass range m/z
50–1000; acquisition rate 1.5 spectra/s; isolation width m/z
*4; and collision energies (CEs) 5, 20 and 35 V. Reten-
tion times for baclofen and gabapentin were 2.02 and
1.96 min, respectively. Positive ionization was performed.
Quantitative and qualitative ions for determinations of
baclofen and gabapentin were m/z 214.0629, 151.0309 and
m/z 172.1332, 154.1226, respectively.
Sample preparation
A 200-lL volume of postmortem blood was poured into a
2-mL Ependorff tube; then 20 lL of gabapentin (IS) at a
concentration of 10 lg/mL was added and mixed. The
blood prepared in such a way was precipitated by adding
drops of 400 lL of frozen 0.1 % formic acid in acetonitrile
(constantly mixed) and the mixing was continued for 30 s.
The samples were centrifuged for 15 min at 20,627g at
5 C (2–16 K, Sigma, Osterode am Harz, Germany).
Subsequently, 400 lL of the supernatant was loaded onto a
column of Phree Phospholipid Removal 1 mL (Phenom-
enex, Torrance, CA, USA) coupled with a polytetrafluo-
roethylene syringe filter (pore size 0.22 lm, FilterBio,
Nantong, China) and filtered using a Visiprep vacuum
manifold (Supelco, Bellefonte, PA, USA) under pressure of
10 mmHg. A 100-lL volume of each of the extracts was
transferred to the inserts and analyzed using LC–QTOF-
MS.
Method validation
Method validation was carried out following the EUR-
ACHEM guidelines [30]. The method was validated by
determining the following parameters: specificity, precision,
recovery, limit of quantification (LOQ) and matrix effect. The
postmortem blood was chosen as a target matrix for method
validation. The specificity of the method was evaluated by
analyzing a blank sample and a blank sample spiked with the
LOQ levels of baclofen and IS. Calibration linearity was
verified by analyzing each of four different blank blood
samples with the additions of baclofen at the concentrations of
1, 2, 5, 10, 20 and 50 lg/mL. Precision was expressed using %
relative standard deviation (%RSD) for each calibration curve
point analyzed in four repeats. Recovery and the matrix effect
were determined for four points of the calibration curve: 1, 5,
10 and 20 lg/mL. Recovery was determined by adding 20 lL
of baclofen and IS, and 400 lL of frozen 0.1 % formic acid in
acetonitrile to 180 lL of water. The solution of standards
prepared in this way was analyzed using LC–QTOF-MS, and
the data were compared with each of the four calibration
curves in postmortem blood. The LOQ in this method was the
blood concentration of baclofen for which both quantitative
and qualitative ions could be observed and the standard
deviation (SD) of the concentration did not exceed 20 %. To
calculate the matrix effect, the formula by Chambers et al. [31]
was applied:





The negative result evidences suppression while the
positive result evidences enhancement of analyte signals.
The validated method was used for analysis of blood
samples sent to the Chair and Department of Forensic
Medicine to determine the cause of death.
Case history
A 25-year-old woman was found dead in her apartment. On
the day of death, the woman consumed an undetermined
amount of drug(s) of unknown origin, which most likely
caused her death. Near the deceased, the following con-
tainers and baclofen tablets were found: one white tablet, 5
mm in diameter, one empty Baclofen 25 mg container for
50 tablets, one full container of the same drug with 51
tablets and one container with 12 and 1/2 tablets. The
above suggested that the woman took 87 and 1/2 tablets
(maximal potential dose 2187.5 mg). The case investiga-
tion revealed that the woman abused alcohol, often had
arguments and caused various problems. Before her death,
she wrote to her boyfriend informing him that she took 100
tablets of baclofen. During the prosecutor’s investigation it
was established that multiple times after arguments with
her boyfriend, the woman had taken various drugs, had
drunk alcohol and subsequently vomited.
External examination and autopsy did not reveal any
pathological changes. There was no ethyl alcohol present in
her blood. Autopsy results excluded death due to mechanical
trauma, acute alcohol intoxication and diseases.
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In this case, postmortem venous blood samples from the
femoral vein were collected via a chemically pure plastic
tube, imblood samples indicated thatthere were impure-
compoundsmediately frozen at -22 C, and stored until
analysis. No anticoagulants were added to the sample.
Results and discussion
The use of HRMS confers high specificity and reduces the
risk of potential interferences related to the complexity of






spectrometry for a blank blood
sample (a), blank blood sample
spiked with 1.0-lg/mL baclofen
and 1.0-lg/mL IS (b), and the
authentic postmortem blood
sample in the present case
spiked with 1.0-lg/mL IS
(c) using the precursor ions
ofbaclofen and IS at a
collisionenergy (CE) of 5 V
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same retention times as those of target substances in blank
blood samples (Fig. 2a)indicated that there were noimpure
compounds that might give false positive signals in these
blank samples. The LOQ for the method was 1 lg/mL,
whereas the coefficient of determination (R2) for the cali-
bration curve was 0.996. Table 1 presents concentrations,
SDs and precisions for individual calibration curve points.
%RSD for the method was 5.1–15.3 %.
Table 2 shows the mean percent recovery rates and
mean matrix effect at four different concentrations of
baclofen in postmortem blood.
The method described enabled detection of baclofen at a
level lower than the LOQ, i.e. 1 lg/mL. The quantitative and
qualitative ions were also observed at the concentration of
0.5 lg/mL; however, at such a wide range of concentrations
(0.5–50 lg/mL), the concentration calculation error for this
point was over 20 %; moreover, reduced linearity was
observed. Therefore, for concentrations up to 0.5 lg/mL, a
separate calibration curve should be constructed. It can be
assumed that the concentration at 0.5 lg/mL of baclofen in
blood was a limit of detection (LOD). The recovery rates in
samples were 90.3–109 %, which confirms that the use of
gabapentin as an IS was the right decision (used earlier for
determination of baclofen in rat materials by Kim et al. [32]
with recoveries of 93.2–100.4 %). The negative matrix
effects evidenced suppression of analyte signals, which
could not be completely removed despite the use of
precipitation, sorbent-removing proteins and phospholipids
as well as filtration during sample preparation.
The presented method has a limitation especially for
quantification of baclofen in postmortem blood. Gaba-
pentin is clinically used for treating epilepsy; as such, there
is potential influence from originally occurring gabapentin.
For this reason, it is important to first analyze the sample
without the IS–gabapentin when using this method.
Qualitative analysis was based on the automatic com-
parison of all ions from the total ion chromatogram to our
database. Crucial criteria included retention time
(±0.5 min.) and mass error (±2 ppm). The qualitative
analysis showed a positive result for baclofen, which was
confirmed by comparison of examined blood samples with
the reference standard of baclofen by product ion mass
spectra, with parameters of the precursor ion at m/z
214.0629, fragmentor voltage at 140 V and CE at 20 V.
The concentration of baclofen determined in the post-
mortem blood was 30.7 lg/mL (n = 4, SD of 1.8 lg/mL;
%RSD of 5.94; Fig. 2c). Tested blood was screened prior
to analysis in order to ensure that it was free from gaba-
pentin. Screening testing did not indicate other compounds
in the biological material.
The application of a QTOF detector enabled obtaining
high-resolution mass spectra (MS/MS). The MS/MS anal-
ysis allowed us to investigate the mechanism of product ion
formation from baclofen, which, to our knowledge, has not
been described before. The obtained product ions of
baclofen may be useful in the determination of this com-
pound by less accurate detectors such as a single quadru-
pole or a triple quadrupole. Depending on the CE, baclofen
underwent product ion formation to three major ions at
m/z 197.03638 (CE 5 V), 151.0309 (CE 20 V) and
116.06205 (CE 35 V), which can be used as confirmation
ions (Fig. 3).
Based on the MS/MS spectra, the general formula of
baclofen fragment ions were suggested (Table 3).
In its structure, baclofen contains one atom of chlorine,
which causes the formation of a characteristic mass spec-
trum evidencing the presence of isotopic ions of this ele-
ment [M ? H:35Cl]? and [M ? H:37Cl]? (Fig. 3, top
panel). The mass difference between chlorine isotopes 35Cl
and 37Cl was 1.9970; therefore, ion fragments with 35Cl
should be accompanied by the ion containing 37Cl, differ-
ing by the value mentioned above. Examinations of the
MS/MS spectra revealed that several very intense frag-
ments were formed as a result of baclofen fragmentation,
depending on the CEs. General formulae were proposed for
six of them (Table 3). The use of HRMS enabled to define
the precise mass of product ions of interest and errors in
their determination as well as to analyze their structure in
detail. At a 5-V CE, the most intense fragment was at
m/z 197.03638. The fragment occurred due to dissociation
Table 1 Calculated concentrations in the calibration curve for









1 1 0.91 0.14 15.3
2 2 2.12 0.20 9.82
5 3 4.99 0.54 10.8
10 4 9.97 0.51 5.08
20 5 20.0 1.21 6.06
50 6 50.4 4.67 9.27
SD standard deviation, RSD relative standard deviation
a Mean of four repeats












a Mean of four repeats
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Fig. 3 High-resolution product ion mass spectra of baclofen obtained at different CEs. The accurate mass of the precursor protonated baclofen
was 214.0629
Table 3 Accurate mass data obtained by liquid chromatography–quadrupole time-of-flight-mass spectrometry and proposed composition of
characteristic product ions of baclofen
No. Proposed composition Observed (m/z) Calculated (m/z) CE (V) Difference (mDa) Difference (ppm) Mass loss Loss formula
1 C10H9ClO2 197.03383 197.03638 5 2.55 12.96 17.02655 NH3
2 C10H10ClNO 196.05123 196.05237 5 1.14 5.81 18.01056 H2O
3 C10H7ClO 179.02329 179.02582 20 7.86 14.12 35.03711 H5NO
4 C9H7Cl 151.02968 151.0309 20 1.22 8.09 63.03203 CH5NO2
5 C7H5Cl 125.01471 125.01525 35 0.54 4.35 89.04768 C3H7NO2
6 C9H7 116.06136 116.06205 35 0.69 5.96 98.00088 CH5ClNO2
CE collision energy
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of the ammonium group from the baclofen molecule.
Figure 3 also contains the 196.05237 ion, which results
from dissociation of a water molecule. This ion was used
by Miksa and Poppenga [33] as one of the confirmation
ions for determinations of baclofen in bovine serum. In our
study, the ion in question was less intense than m/
z 197.03638, which is likely to be associated with a type of
ionization different from that applied by Miksa and Pop-
penga, i.e. atmospheric pressure chemical ionization [33].
The ion at m/z 179.02582 (C10H7
35ClO) is formed due
to dissociation of both the water molecule and ammonium
group and not the loss of chlorine (as suggested by Miksa
and Poppenga [33]), because the ion at m/z 181.02282
(C10H7
37ClO), characteristic of a chlorine isotope, was also
visible in Fig. 3 (top panel). The use of a medium colli-
sion energy (CE = 20 V) resulted in the most intense
signal coming from the fragment C9H7Cl at m/z 151.0309.
The signal occurs due to dissociation of the CO2 group
and ammonium group from the baclofen molecule. The
next stages of product formation involve dissociation of
the chlorine atom from the ion at m/z 151.0309 and
cyclization of its propylene group, leading to formation of
the C9H7 = 116.06205 fragment, which was the most
intense ion at CE = 35 V (Fig. 3, bottom panel and
Fig. 4).
In medico-legal toxicology, the cases of fatal intoxi-
cation with baclofen alone are rare, as compared to
intoxications with other drugs affecting the CNS. The
likely causes of baclofen overdose include adaptive and
personality disorders as well as depression, leading to
suicidal attempts. The literature reports also described
cases of accidental consumption of baclofen by children
[34–36]. Table 4 lists the cases of baclofen intoxication
reported in literature. Only in one case of fatal baclofen
intoxication were no other xenobiotics found, which
could interact with baclofen. In the case described in the
present study, toxicological analysis of the blood
demonstrated a concentration of baclofen at 30.7 lg/mL,
which markedly exceeds the lethal dose (6–9.6 lg/mL
according to TIAFT data) [37]. In only one case descri-
bed by Giovanni and d’Aloja [18] was the blood con-
centration of baclofen found to be higher than that in our
case; moreover, they identified other xenobiotics in their
material as well.
Fig. 4 Probable product-ion
formation pathways from the
protonated baclofen precursor
ion
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Conclusions
The application of HRMS enables reliable identification
of baclofen in autopsy blood. The method designed is
characterized by high-efficiency extraction. The study
findings demonstrate that the specific, simple and quick
procedure described by us for determination of baclofen
in autopsy blood can be successfully used for routine
toxicology testing in the cases of suspected baclofen
intoxication. Unambiguous identification of baclofen is
derived from the available product ion mass spectrum. In
such a spectrum, we observed three product ions of
baclofen (m/z 197.03638, 151.0309 and 116.06205) of
high intensity. These product ions may be successfully
employed as confirmative ions in QTOF-MS or triple-
quadrupole-MS analysis. Using the obtained tandem mass
spectra and defined accurate masses, we proposed the
pathways of product ion formation from baclofen. How-
ever, the method has a limitation associated with the use
of gabapentin as an IS instead of a stable isotope-labeled
IS, which is why tested blood should be screened prior to
analyzing to ensure that it is free from gabapentin. To our
knowledge, this is the first report for analysis of baclofen
by HRMS.
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